The CCEL stock plunged in pre-market trade on 16 Mar 2026, reflecting a near-total price collapse and a fresh NYSE American compliance notice. Traders show unusually high activity with volume 29,717 versus average 12,358, while the quote data lists a day high of $3.12 and a reported open and prior close of $3.11. This note explains drivers, valuation, technical signals, Meyka AI grading, and short-term forecasts for Cryo-Cell International, Inc. (NASDAQ) to help investors weigh listing and liquidity risk.
CCEL stock pre-market move and immediate facts
CCEL stock showed a dramatic pre-market move on 16 Mar 2026, with a reported one-day change of -100.00% and an intraday high of $3.12. Trading volume stood at 29,717, roughly 2.39x the average volume of 12,358, indicating concentrated selling pressure.
The company’s year range is between $2.89 and $6.99, and market capitalization reads about $23,521,038.00. These figures frame today’s drop as a high-risk event for shareholders and short-term traders.
Why the drop: NYSE American notice and news links
A formal non-compliance notice from NYSE American is the clearest catalyst for the price move and investor concern. The notice raises potential listing risks that can amplify sell-side flows and reduce liquidity source.
Company profile and financial filings are being referenced by market services, increasing attention to fundamentals and cash metrics amid the sell-off source. These reports likely influenced pre-market positioning.
CCEL stock valuation and balance-sheet snapshot
Cryo-Cell International shows trailing EPS of -0.30 and a negative PE near -9.73, reflecting losses. Price-to-sales is 0.74, and free cash flow yield is approximately 22.54%, suggesting operating cash generation despite net losses.
Liquidity metrics are thin: current ratio 0.59 and cash per share $0.41. Book value per share is negative at -2.31, and shareholders’ equity per share stands at -2.31, underscoring capital constraints and balance-sheet risk.
Technicals, trading signals, and Meyka AI rates CCEL with a score out of 100
Most technical signals point to severe oversold conditions: RSI 18.85, CCI -200.98, and Williams %R -94.34. Momentum is negative with recent performance down 55.01% year-over-year. Average and real-time volumes show elevated selling interest.
Meyka AI rates CCEL with a score out of 100: 69.32 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. These grades are informational only and not guaranteed; we are not financial advisors.
CCEL stock price forecasts and model projections
Meyka AI’s forecast model projects a monthly price of $2.22, a quarterly target of $1.60, and a yearly projection of $1.84. Compared with the last trade near $3.11, the model implies a -40.87% downside to the yearly projection, and -28.62% to the monthly projection.
Forecasts are model-based projections and not guarantees. With no consensus price target available, traders should treat these model levels as scenario anchors rather than firm guidance.
Investor takeaways: risks, sector context, and trading strategy
Primary near-term risks are listing status, low liquidity, and negative book value per share. The healthcare sector can provide defensive flows, but CCEL’s small market cap and compliance notice make it a speculative position.
For active traders, watch intraday volume, bid-ask spreads, and regulatory updates. For investors, consider the balance between a high free cash flow yield and structural balance-sheet concerns before adding CCEL stock to a portfolio.
Final Thoughts
CCEL stock faces concentrated downside risk after the NYSE American compliance notice and pre-market selling on 16 Mar 2026. Key market data show open $3.11, day high $3.12, volume 29,717, and market cap $23,521,038.00, consistent with thin liquidity and volatile trading. Meyka AI’s forecast model projects a yearly price of $1.84, implying -40.87% from the last trade near $3.11. Meyka AI rates CCEL with a 69.32 score (Grade B, HOLD) after weighing benchmark and sector comparisons, financial growth, and technicals. Forecasts are model projections and not guarantees. Short-term traders should prioritize liquidity and regulatory updates; longer-term investors must weigh free cash flow strength against negative book value and listing risk. We mention these findings as data-driven market analysis from Meyka AI, an AI-powered market analysis platform, not as investment advice.
FAQs
Why did CCEL stock fall pre-market on 16 Mar 2026?
The drop followed a NYSE American non-compliance notice and heavy selling. Pre-market volume rose to 29,717 versus average 12,358, signaling concentrated exits tied to listing concerns.
What is Meyka AI’s forecast for CCEL stock?
Meyka AI’s model projects a monthly price of $2.22, a quarterly price of $1.60, and a yearly price of $1.84. These are model projections and not guarantees.
How does valuation look for CCEL stock right now?
Valuation shows EPS -0.30, PE -9.73, price-to-sales 0.74, negative book value per share -2.31, and free cash flow yield 22.54%, a mixed fundamental picture.
Should I trade CCEL stock now given the volatility?
Trading CCEL stock now is high risk. Watch regulatory updates, bid-ask spreads, and volume. Small market cap and compliance notices raise listing and liquidity risks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)